Seminars in Oncology
Volume 31, Issue 2 , Pages 198-205 , April 2004

Lymphoma and myeloma in older patients

  • Eric H Westin

      Affiliations

    • Section of Hematology/Oncology, Laboratory of Clinical Investigation, National Institute on Aging/National Institute of Health, Baltimore, MD, USA
    • Corresponding Author InformationAddress reprint requests to Eric H. Westin, MD, National Institute on Aging/National Institute of Health, 5600 Nathan Shock Dr, Baltimore, MD 21224-6825 USA
    • ,
  • Dan L Longo

      Affiliations

    • Section of Hematology/Oncology, Laboratory of Clinical Investigation, National Institute on Aging/National Institute of Health, Baltimore, MD, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  2. Kyle RA, Gertz MA, Witzig TE, et al.  Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33
  3. Proctor SJ, Rueffer JU, Angus B, et al.  Hodgkin’s disease in the elderly (current status and future directions). Ann Oncol. 2002;13:133–137
  4. Stark GL, Wood KM, Jack F, et al.  Hodgkin’s disease in the elderly (a population-based study). Br J Haematol. 2002;119:432–440
  5. Nilsson T, Hoglund M, Lenhoff S, et al.  A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol. 2003;120:960–969
  6. Konigsberg R, Zojer N, Ackermann J, et al.  Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804–812
  7. Hedvat CV, Hegde A, Chaganti RS, et al.  Application of tissue microarray technology to the study of non-Hodgkin’s and Hodgkin’s lymphoma. Hum Pathol. 2002;33:968–974
  8. Garcia JF, Camacho FI, Morente M, et al.  Hodgkin and Reed-Stemberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints (Analyses using tissue microarrays). Blood. 2003;101:681–689
  9. Mao X, Lillington D, Child F, et al.  Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas (Identification of common genomic alterations in disease pathogenesis). Genes Chromosomes Cancer. 2002;35:144–155
  10. Alizadeh AA, Eisen MB, Davis RE, et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  11. Harris NL, Jaffe ES, Diebold J, et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999;10:1419–1432
  12. Harris NL, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms (a proposal from the International Lymphoma Study Group). Blood. 1994;84:1361–1392
  13. Jaffe ES, Harris NL, Diebold J, et al.  World Health Organization Classification of lymphomas (A work in progress). Ann Oncol. 1998;9(suppl 5):S25–S30
  14. Cuttner J, Wallenstein S, Troy K. Non-Hodgkin’s lymphoma in patients 70 years of age or older (factors associated with survival). Leuk Res. 2002;26:447–450
  15. Maartense E, Le C, Kluin-Nelemans HC, et al.  Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems (Analysis from a population-based non-Hodgkin’s lymphoma registry). Ann Oncol. 2002;13:1275–1284
  16. Effect of age on the characteristics and clinical behavior of non- Hodgkin’s lymphoma patients. The Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1997;8:973–978
  17. The Danish LYEO-Study Group d’Amore F, Brincker H, Christensen BE, et al.  Non-Hodgkin’s lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Ann Oncol. 1992;3:379–386
  18. Peters FPJ, Lalisang RI, Fickers MMF, et al.  Treatment of elderly patients with intermediate- and high-grade non-Hodgkin’s lymphoma (A retrospective population-based study). Ann Hematol. 2001;80:155–159
  19. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, et al.  Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, 1993–1996. Ann Hematol. 1999;78:315–319
  20. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly (Increased complications with advancing age). J Am Geriatr Soc. 1984;32:269–273
  21. Lee MA, Segal GM, Bagby GC. The hematopoietic microenvironment in the elderly (Defects in IL-1-induced CSF expression in vitro). Exp Hematol. 1989;17:952–956
  22. Morris CL, Siegel E, Barlogie B, et al.  Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma (Influence of age, prior therapy, platelet count and mobilization regimen). Br J Haematol. 2003;120:413–423
  23. Niitsu N, Iijima K. Full-dose CHOP chemotherapy combined with granulocyte colony-stimulating factor for aggressive non-Hodgkin’s lymphoma in elderly patients (A prospective study). Ann Hematol. 2001;80:602–606
  24. Sotaniemi EA, Arranto AJ, Pelkonen O, et al.  Age and cytochrome P450-linked drug metabolism in humans (An analysis of 226 subjects with equal histopathologic conditions). Clin Pharmacol Ther. 1997;61:331–339
  25. Lichtman SM, Villani G. Chemotherapy in the elderly (pharmacologic considerations). Cancer Control. 2000;7:548–556
  26. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13:169–183
  27. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol. 2002;29:18–22
  28. Siegel DS, Desikan KR, Mehta J, et al.  Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999;93:51–54
  29. Wilson WH, Grossbard ML, Pittaluga S, et al.  Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas (A pharmacodynamic approach with high efficacy). Blood. 2002;99:2685–2693
  30. Chisesi T, Federico M, Levis A, et al.  ABVD versus Stanford V versus MEC in unfavourable Hodgkin’s lymphoma (results of a randomised trial). Ann Oncol. 2002;13:102–106
  31. Zinzani PL, Magagnoli M, Frezza G, et al.  ABVD and radiation therapy as first-line treatment in advanced Hodgkin’s disease. Leuk Lymphoma. 1999;32:553–559
  32. French Cooperative Group on Chronic Lymphocytic Leukemia Dighiero G, Maloum K, Desablens B, et al.  Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med. 1998;338:1506–1514
  33. Dighiero G. Chronic lymphocytic leukemia treatment. Hematol Cell Ther. 1997;39(suppl 1):S31–S40
  34. Besa PC, McLaughlin PW, Cox JD, et al.  Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer. 1995;75:2361–2367
  35. Cole BF, Solal-Celigny P, Gelber RD, et al.  Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma (An aid to clinical decision making). J Clin Oncol. 1998;16:2339–2344
  36. McLaughlin P, Hagemeister FB, Swan F, et al.  Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma (high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement). Ann Oncol. 1994;5(suppl 2):73–77
  37. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999;26:88–96
  38. Kimby E, Bjorkholm M, Gahrton G, et al.  Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin’s lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol. 1994;5(suppl 2):67–71
  39. Ghielmini M, Schmitz SF, Cogliatti S, et al.  Prolonged treatment with Rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma (A randomized SAKK trial). Blood. 2002;100:161a; (abstr)
  40. Martinelli G, Laszlo D, Mancuso P, et al.  Rituximab plus chlorambucil in low grade non-Hodgkin’s lymphomas (NHL) (Clinical results of a phase II study). Blood. 2002;100:777a; (abstr)
  41. Osby E, Hagberg H, Kvaloy S, et al.  CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment (Results of a Nordic Lymphoma Group randomized trial). Blood. 2003;101:3840–3848
  42. Coiffier B, Lepage E, Briere J, et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  43. Mounier N, Briere J, Gisselbrecht C, et al.  Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL) overcomes bcl2-associated chemotherapy resistance. Blood. 2002;100:161a; (abstr)
  44. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484–489
  45. Richardson PG, Barlogie B, Berenson J, et al.  A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609–2617
  46. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329. 1993;987–994
  47. Anderson KC, Hamblin TJ, Traynor A. Management of multiple myeloma today. Semin Hematol. 1999;36:3–8
  48. Aviles A. The International Index is not useful in the classification of low-grade lymphoma. J Clin Oncol. 1994;12:2766–2768 (letter)
  49. Bastion Y, Coiffier B. Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients?. J Clin Oncol. 1994;12:1340–1342
  50. Carbone PP, Kaplan HS, Musshoff K, et al.  Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31:1860–1861
  51. Crowther D, Lister TA. The Cotswolds report on the investigation and staging of Hodgkin’s disease. Br J Cancer. 1990;62:551–552 (editorial)

PII: S0093-7754(03)00668-7

doi: 10.1053/j.seminoncol.2003.12.030

Seminars in Oncology
Volume 31, Issue 2 , Pages 198-205 , April 2004

Article Tools